Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
566.00K | 391.69K | 1.50M | 208.38M | 12.62M | Gross Profit |
566.00K | 391.69K | 121.14K | 208.38M | 12.62M | EBIT |
-61.88M | -59.28M | -55.55M | 124.21M | -81.43M | EBITDA |
-61.88M | -57.69M | -52.79M | 124.40M | -81.12M | Net Income Common Stockholders |
-26.43M | -52.34M | -51.41M | 122.83M | -80.73M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
53.08M | 105.83M | 129.00M | 187.80M | 72.03M | Total Assets |
92.17M | 144.03M | 155.27M | 194.54M | 75.93M | Total Debt |
1.34M | 16.00M | 16.54M | 0.00 | 0.00 | Net Debt |
-24.96M | -11.04M | -112.47M | -187.80M | -72.03M | Total Liabilities |
23.94M | 56.23M | 22.99M | 14.80M | 32.29M | Stockholders Equity |
68.23M | 87.80M | 132.27M | 179.75M | 43.63M |
Cash Flow | Free Cash Flow | |||
-56.03M | -45.92M | -56.65M | 118.42M | -51.97M | Operating Cash Flow |
-55.96M | -45.78M | -55.23M | 118.61M | -51.58M | Investing Cash Flow |
54.59M | -2.58M | -87.88M | -1.82M | 34.65M | Financing Cash Flow |
622.00K | 30.54M | 180.66K | 904.08K | 47.07M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
68 Neutral | $5.28B | 22.84 | 19.71% | ― | 52.97% | ― | |
54 Neutral | $3.05B | ― | -214.50% | ― | 29.01% | 23.93% | |
48 Neutral | $6.35B | 1.19 | -46.87% | 2.63% | 17.16% | 1.34% | |
46 Neutral | $451.14M | ― | -35.41% | ― | -39.92% | 7.38% | |
44 Neutral | $20.01M | ― | -33.88% | ― | 44.50% | 49.72% | |
39 Underperform | $85.47M | ― | -98.10% | ― | -58.64% | -40.05% | |
31 Underperform | $28.99M | ― | -554.86% | ― | ― | ― |
On March 1, 2025, Ovid Therapeutics expanded its Board of Directors by appointing Stelios Papadopoulos, Ph.D., as a Class I director, increasing the board size from five to six members. Dr. Papadopoulos, a seasoned executive with extensive experience in the biotechnology sector, joins the Audit and Compensation Committees, bringing valuable expertise from his previous roles at Exelixis, Inc., Regulus Therapeutics Inc., and other biopharmaceutical companies. This strategic appointment is expected to enhance Ovid’s governance and potentially strengthen its position in the biotechnology industry.